Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Descriptor ID |
D019008
|
MeSH Number(s) |
G07.690.773.984.395
|
Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 2 | 2 | 1998 | 0 | 3 | 3 | 1999 | 0 | 2 | 2 | 2000 | 1 | 2 | 3 | 2001 | 0 | 3 | 3 | 2002 | 0 | 2 | 2 | 2003 | 0 | 4 | 4 | 2004 | 1 | 1 | 2 | 2005 | 3 | 4 | 7 | 2006 | 0 | 3 | 3 | 2007 | 4 | 10 | 14 | 2008 | 4 | 4 | 8 | 2009 | 7 | 6 | 13 | 2010 | 9 | 12 | 21 | 2011 | 4 | 9 | 13 | 2012 | 6 | 14 | 20 | 2013 | 10 | 16 | 26 | 2014 | 11 | 11 | 22 | 2015 | 12 | 13 | 25 | 2016 | 12 | 25 | 37 | 2017 | 10 | 20 | 30 | 2018 | 12 | 20 | 32 | 2019 | 15 | 11 | 26 | 2020 | 10 | 9 | 19 | 2021 | 12 | 10 | 22 | 2022 | 4 | 5 | 9 | 2023 | 1 | 6 | 7 | 2024 | 9 | 8 | 17 | 2025 | 6 | 6 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, J?nne PA, Wang M. Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Cell Rep Med. 2025 May 20; 6(5):102121.
-
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL. A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatr Blood Cancer. 2025 Jul; 72(7):e31692.
-
Karol SE, Khaw SL, Zwaan CM, Baruchel A, Bittencourt H, Cooper TM, Flotho C, Fraser C, Forlenza CJ, Goldsmith KC, Macy ME, Morgenstern DA, O'Brien MM, Petit A, Ziegler DS, Reinhardt D, Opferman JT, Rubnitz JE, Onishi M, Dunshee DR, Dunbar F, Vishwamitra D, Ross JA, Chen X, Unnebrink K, Kammerlander M, Salem AH, Palenski TL, Sunkersett G, Place AE. Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. Pediatr Blood Cancer. 2025 Jul; 72(7):e31714.
-
Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N. Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J. 2025 Mar 26; 15(1):45.
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
-
Ding K, Chen L, Levine KM, Sikora MJ, Tasdemir N, Dabbs D, Jankowitz R, Hazan R, Shah O, Atkinson J, Lee AV, Oesterreich S. FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role. Breast Cancer Res Treat. 2025 Jun; 211(2):501-515.
-
Ward AV, Riley D, Cosper KE, Finlay-Schultz J, Brechbuhl HM, Libby AE, Hill KB, Varshney RR, Kabos P, Rudolph MC, Sartorius CA. Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells. Breast Cancer Res. 2025 Mar 07; 27(1):32.
-
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Strang JE, Astridge DD, Nguyen VT, Reigan P. Small Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy. J Med Chem. 2025 Feb 13; 68(3):2238-2254.
-
Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman J. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025 May; 36(5):583-591.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|